Education
About Us
Working with TipRanks
Follow Us
Evommune, Inc. (EVMN)
NYSE:EVMN
EVMN Stock Chart & Stats
$23.56
--
Market closed
$23.56
--
Day’s Range― - ―
52-Week Range$13.89 - $33.20
Previous CloseN/A
VolumeN/A
Average Volume (3M)935.27K
Market Cap
$840.31M
Enterprise Value$258.28M
Total Cash (Recent Filing)$149.20M
Total Debt (Recent Filing)$2.06M
Price to Earnings (P/E)―
Beta-0.92
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding36,018,370
10 Day Avg. Volume412,591
30 Day Avg. Volume935,274
Financial Highlights & Ratios
PEG Ratio1.98
Price to Book (P/B)2.63
Price to Sales (P/S)41.51
P/FCF Ratio-7.04
Enterprise Value/Market Cap0.31
Enterprise Value/Revenue19.87
Enterprise Value/Gross Profit22.24
Enterprise Value/Ebitda-3.75
Forecast
1Y Price Target
$49.25Price Target Upside109.04% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth TrajectoryEvommune's multi-year revenue increase from $5M to $13M demonstrates durable top-line traction and growing commercial or collaboration uptake. Sustained revenue scaling improves prospects for leveraging fixed R&D and SG&A, helping unit economics as clinical programs convert to broader indications and market penetration.
Material Balance Sheet StrengtheningA dramatic recapitalization and sharply reduced leverage materially lower insolvency and refinancing risk, providing durable financial flexibility. Stronger equity and higher assets support multi-year clinical investment, partnership options, and buffer operational volatility typical in biotech development cycles.
Clinical Validation And Pipeline MomentumPhase 2a proof-of-concept for EVO301 validates IL-18 inhibition and de-risks a lead program structurally. Statistically significant efficacy, safety and biomarker reductions support progression to Phase 2b and broader indications, strengthening long-term commercial potential and strategic partnering or licensing options.
Bears Say
Large Persistent Net LossesSustained multi-year net losses indicate the company remains far from operating profitability; this structural loss profile pressures long-term margins and requires consistent funding or rapid scale-up. Without demonstrated path to margin improvement, losses constrain strategic choices and investor returns.
Accelerating Negative Cash GenerationWorsening operating and free cash flow over successive years shows rising burn and negative cash conversion. This persistent, increasing outflow creates structural financing needs and raises execution risk: the company must either increase revenue materially or cut spend to avoid repeated dilutive capital raises.
Dependence On External FinancingReliance on a large private placement to fund operations underscores dependence on external capital. While it extends runway, it creates dilution risk and makes long-term viability contingent on clinical success or future financings, a structural vulnerability until programs generate sustainable revenues.
Evommune, Inc. News
EVMN FAQ
What was Evommune, Inc.’s price range in the past 12 months?
Evommune, Inc. lowest stock price was $13.88 and its highest was $33.20 in the past 12 months.
What is Evommune, Inc.’s market cap?
Evommune, Inc.’s market cap is $840.31M.
When is Evommune, Inc.’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Evommune, Inc.’s earnings last quarter?
Currently, no data Available
Is Evommune, Inc. overvalued?
According to Wall Street analysts Evommune, Inc.’s price is currently Undervalued.
Does Evommune, Inc. pay dividends?
Evommune, Inc. does not currently pay dividends.
What is Evommune, Inc.’s EPS estimate?
Evommune, Inc.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Evommune, Inc. have?
Evommune, Inc. has 36,018,370 shares outstanding.
What happened to Evommune, Inc.’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Evommune, Inc.?
Currently, no hedge funds are holding shares in EVMN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Evommune, Inc. Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$49.25 (109.04% Upside)
$49.25 (109.04% Upside)
Blogger Sentiment
Bullish
EVMN Sentiment 100%
Sector Average 69%
Sector Average 69%
Insider Transactions
Bought Shares
Worth $17.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.0%
Last 30 Days ▲ 4.6%
Last 30 Days ▲ 4.6%
News Sentiment
Bullish
Bullish news 67%
Bearish news 33%
Bearish news 33%
Company Description
Evommune, Inc.
Evommune, Inc. operates as a clinical-stage biotechnology company in the United States. It develops therapies that target key drivers of chronic inflammatory diseases, with initial clinical development programs focusing on chronic spontaneous urticaria, atopic dermatitis, and ulcerative colitis. Its products includes EVO756 for the treatment of CSU and AD; and EVO301 for the treatment of AD and UC. The company was incorporated in 2020 and is based in Palo Alto, California.
EVMN Stock 12 Month Forecast
Average Price Target
$49.25
▲(109.04% Upside)